CA2249213A1 - Proteine extracellulaire/epidermique de type facteur de croissance - Google Patents

Proteine extracellulaire/epidermique de type facteur de croissance Download PDF

Info

Publication number
CA2249213A1
CA2249213A1 CA002249213A CA2249213A CA2249213A1 CA 2249213 A1 CA2249213 A1 CA 2249213A1 CA 002249213 A CA002249213 A CA 002249213A CA 2249213 A CA2249213 A CA 2249213A CA 2249213 A1 CA2249213 A1 CA 2249213A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
dna
cells
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002249213A
Other languages
English (en)
Inventor
Henrik S. Olsen
Haodong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP96912802A priority Critical patent/EP0910569A4/fr
Priority to CA002249213A priority patent/CA2249213A1/fr
Priority to PCT/US1996/005247 priority patent/WO1997038002A1/fr
Priority to JP09536143A priority patent/JP2000508531A/ja
Priority to AU55492/96A priority patent/AU5549296A/en
Publication of CA2249213A1 publication Critical patent/CA2249213A1/fr
Priority to US09/275,805 priority patent/US20010051358A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

L'invention porte sur un polypeptide extracellulaire/épidermique facteur de croissance et sur des polynucléotides codant ce polypeptide. Sont également proposés un procédé pour produire de tels polypeptides par des techniques recombinantes et des applications thérapeutiques de ces polypeptides, comprenant l'induction d'une synthèse d'ADN, la stimulation de la guérison des plaies, le traitement de troubles neurologiques, le traitement de problèmes oculaires, rénaux, ou hépatiques ainsi que la stimulation de l'embryogenèse et de l'angiogenèse. L'invention décrit en outre les antagonistes de ces polypeptides et leur utilisation thérapeutique dans le traitement de néoplasmes. Enfin elle propose des méthodes diagnostiques pour détecter les variations dans les taux de ces polypeptides et les mutations intervenant dans les séquences d'acide nucléique qui codent ces mêmes polypeptides.
CA002249213A 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance Abandoned CA2249213A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP96912802A EP0910569A4 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance
CA002249213A CA2249213A1 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance
PCT/US1996/005247 WO1997038002A1 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance
JP09536143A JP2000508531A (ja) 1996-04-10 1996-04-10 細胞外／上皮増殖因子様タンパク質
AU55492/96A AU5549296A (en) 1996-04-10 1996-04-10 Extracellular/epidermal growth factor-like protein
US09/275,805 US20010051358A1 (en) 1996-04-10 1999-03-25 Extracellular/epidermal growth factor-like protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002249213A CA2249213A1 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance
PCT/US1996/005247 WO1997038002A1 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance

Publications (1)

Publication Number Publication Date
CA2249213A1 true CA2249213A1 (fr) 1997-10-16

Family

ID=25680533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249213A Abandoned CA2249213A1 (fr) 1996-04-10 1996-04-10 Proteine extracellulaire/epidermique de type facteur de croissance

Country Status (5)

Country Link
EP (1) EP0910569A4 (fr)
JP (1) JP2000508531A (fr)
AU (1) AU5549296A (fr)
CA (1) CA2249213A1 (fr)
WO (1) WO1997038002A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972021A1 (fr) * 1997-04-11 2000-01-19 Human Genome Sciences, Inc. Proteine semblable au facteur de croissance extracellulaire/epidermique
US5872234A (en) 1997-06-27 1999-02-16 Incyte Pharmaceuticals, Inc. Human extracellular matrix proteins
US6300311B1 (en) 1998-04-14 2001-10-09 Texas Tech University Regulation of vertebrate ovarian maturation and function using growth factors
WO1999055863A1 (fr) * 1998-04-28 1999-11-04 Ono Pharmaceutical Co., Ltd. Nouveau polypeptide, adnc le codant et son utilisation
AUPP489798A0 (en) * 1998-07-28 1998-08-20 Mediko Pty Ltd Hair growth/maintenance compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000369A1 (fr) * 1983-07-05 1985-01-31 Chiron Corporation Synthese a l'aide d'adn hybride du facteur de croissance epidermique
FI891308A (fi) * 1988-03-24 1989-09-25 Oncogen Nya polypeptider med tillvaextfaktoraktivitet och dessa kodande nukleinsyrasekvenser.

Also Published As

Publication number Publication date
EP0910569A1 (fr) 1999-04-28
WO1997038002A1 (fr) 1997-10-16
EP0910569A4 (fr) 2002-05-08
JP2000508531A (ja) 2000-07-11
AU5549296A (en) 1997-10-29

Similar Documents

Publication Publication Date Title
US6884594B2 (en) Antibodies to growth factor HTTER36
US5916769A (en) Polynucleotides encoding extra cellular/epidermal growth factor HCABA58X polypepides
US20100130417A1 (en) Transforming growth factor alpha hii
WO1997025349A1 (fr) Facteur transformant de croissance alpha hiii
AU717005B2 (en) Transforming growth factor alpha HI
CA2215350C (fr) Facteur de croissance transformant alpha hii
CA2249213A1 (fr) Proteine extracellulaire/epidermique de type facteur de croissance
AU752206B2 (en) Extracellular/epidermal growth factor like protein
US5844081A (en) Cytostatin I
US20060286593A1 (en) Transforming Growth Factor Alpha HI
US7393832B2 (en) Extracellular/epidermal growth factor like protein
US6852506B1 (en) Extracellular/epidermal growth factor-like protein
EP0891372B1 (fr) Facteur de croissance htter36
AU745802B2 (en) Transforming growth factor alpha HII
AU780633B2 (en) Transforming growth factor alpha HII
US20040229787A1 (en) Transforming growth factor alpha Hlll
EP1881069A1 (fr) Facteur transformant de croissance alpha HII
AU2887100A (en) Transforming growth factor alpha HI
JP2004000186A (ja) 細胞外／上皮増殖因子様タンパク質

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead